SlateStone Wealth’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.92M | Sell |
35,440
-724
| -2% | -$156K | 0.68% | 46 |
|
|
2026
Q1 | $7.87M | Buy |
36,164
+604
| +2% | +$134K | 0.65% | 50 |
|
|
2025
Q4 | $8.13M | Sell |
35,560
-1,047
| -3% | -$239K | 0.68% | 47 |
|
|
2025
Q3 | $8.48M | Sell |
36,607
-2,563
| -7% | -$522K | 0.73% | 43 |
|
|
2025
Q2 | $7.27M | Buy |
39,170
+639
| +2% | +$119K | 0.68% | 47 |
|
|
2025
Q1 | $8.07M | Sell |
38,531
-3,650
| -9% | -$710K | 0.81% | 39 |
|
|
2024
Q4 | $7.5M | Buy |
42,181
+15
| +0% | +$2.76K | 0.74% | 43 |
|
|
2024
Q3 | $8.33M | Sell |
42,166
-445
| -1% | -$83.1K | 0.75% | 38 |
|
|
2024
Q2 | $7.31M | Sell |
42,611
-3,877
| -8% | -$642K | 0.79% | 33 |
|
|
2024
Q1 | $8.46M | Buy |
46,488
+5,397
| +13% | +$930K | 0.85% | 34 |
|
|
2023
Q4 | $6.37M | Buy |
41,091
+56
| +0.1% | +$8.16K | 0.83% | 32 |
|
|
2023
Q3 | $6.12M | Buy |
41,035
+17,051
| +71% | +$2.5M | 0.89% | 28 |
|
|
2023
Q2 | $3.23M | Sell |
23,984
-1,045
| -4% | -$153K | 0.61% | 37 |
|
|
2023
Q1 | $3.99M | Buy |
25,029
+242
| +1% | +$37K | 0.83% | 25 |
|
|
2022
Q4 | $4.01M | Buy |
24,787
+1,967
| +9% | +$302K | 0.97% | 25 |
|
|
2022
Q3 | $3.06M | Sell |
22,820
-224
| -1% | -$32.1K | 0.82% | 27 |
|
|
2022
Q2 | $3.53M | Buy |
23,044
+1,272
| +6% | +$194K | 0.9% | 25 |
|
|
2022
Q1 | $3.53M | Sell |
21,772
-4,291
| -16% | -$623K | 0.79% | 29 |
|
|
2021
Q4 | $3.53M | Buy |
26,063
+2,843
| +12% | +$336K | 0.75% | 34 |
|
|
2021
Q3 | $2.5M | Buy |
23,220
+3,911
| +20% | +$447K | 0.57% | 41 |
|
|
2021
Q2 | $2.17M | Sell |
19,309
-91
| -0.5% | -$10.2K | 0.5% | 50 |
|
|
2021
Q1 | $2.1M | Sell |
19,400
-760
| -4% | -$81.3K | 0.52% | 49 |
|
|
2020
Q4 | $2.16M | Sell |
20,160
-2,279
| -10% | -$219K | 0.54% | 51 |
|
|
2020
Q3 | $1.97M | Sell |
22,439
-5,554
| -20% | -$523K | 0.42% | 63 |
|
|
2020
Q2 | $2.75M | Buy |
27,993
+15,491
| +124% | +$1.36M | 0.61% | 49 |
|
|
2020
Q1 | $953K | Sell |
12,502
-14,228
| -53% | -$1.21M | 0.27% | 87 |
|
|
2019
Q4 | $2.37M | Buy |
26,730
+500
| +2% | +$41.5K | 0.54% | 50 |
|
|
2019
Q3 | $1.99M | Sell |
26,230
-8,395
| -24% | -$576K | 0.58% | 47 |
|
|
2019
Q2 | $2.52M | Buy |
34,625
+165
| +0.5% | +$13K | 0.71% | 40 |
|
|
2019
Q1 | $2.78M | Buy |
34,460
+7,180
| +26% | +$587K | 0.85% | 33 |
|
|
2018
Q4 | $2.52M | Buy |
+27,280
| New | +$2.4M | 1.16% | 24 |
|
Other funds holding ABBV
ECSS
ATO
SlateStone Wealth's ABBV Position: Q2 2026 in Review
SlateStone Wealth reduced its AbbVie (ABBV) stake by 2% in Q2 2026, selling an estimated $156K and leaving 35,440 shares worth $8.92M. The position accounts for 0.68% of the portfolio, ranked #46.
SlateStone Wealth first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 1,885 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- SlateStone Wealth held 35,440 shares of AbbVie worth $8.92M as of Q2 2026.
- SlateStone Wealth sold 724 AbbVie shares in Q2 2026, an estimated $156K.
- AbbVie made up 0.68% of SlateStone Wealth's portfolio in Q2 2026, its #46 holding.
- SlateStone Wealth first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 1,885 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on SlateStone Wealth's 13F filing for Q2 2026, filed 20 Jul 2026.